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CHAPTER 1
INTRODUCTION
Laryngeal squamous-cell carcinomas (LSCC) comprise the vast majority 
(96%) of laryngeal malignancies  1.  Larynx has several clinical and molecular 
peculiarities. The American Cancer Society classifies the larynx as part of the 
respiratory system, separate from the oral cavity and pharynx 2  
Most of these tumors originate in the glottis and supra glottis; the sub 
glottis is an extremely rare site of origin. The estimated incidence of cervical 
lymph-node metastases with no obvious primary site (occult T) is from 3% to 
9% 5, 6 and some of these might reasonably have a laryngeal (especially supra 
glottic) origin. The male/female ratio for the incidence of laryngeal cancer is 
much higher than in other parts of the head and neck 2.
  Differences  in  chromosomal  pattern  and  carcinogenic  progression 
between LSCC and other head-and-neck squamous-cell  carcinomas (HNSCC) 
have been detected by comparative genomic studies 3.
 Practically  all  patients  (95%)  with  LSCC have  a  history  of  tobacco 
smoking, which increases risk in a dose-dependent way.  
 
 The standard options for treatment of LSCC are surgery, radiotherapy, 
chemotherapy, or a combination of these.  Radiotherapy is  used in more than 
70% of patients, surgery in about 55% and chemotherapy in about 10%. It is 
widely  accepted  that  most  early-stage  LSCC can be  adequately  treated  with 
single-modality  therapy,  whether  surgery  or  irradiation,  with  a  5-year  local 
control of 85–98% 10, 13, 14.
A  multimodality  approach  based  upon  a  combination  of  surgery  and 
irradiation is the most common treatment for stage III and IV Disease 1.              
The increasing use of chemo, radiotherapy and more conservative surgery 
to preserve organs and their function 1   may have led to a better quality of life 
for LSCC patients, but has clearly failed to improve survival, which remains the 
primary aim. 
Five  year  survival  rates  for  cancer  of  the  larynx  did  not  show  any 
improvement over the last 30 years 2. In LSCC, we can identify several potential 
reasons for this failure.   
 
The majority of patients with LSCC (more than 60%), especially glottic 
cancers, present with early stage disease, and early diagnosis remains the best 
predictor for survival. There is a reported increase in patients diagnosed with 
stage IV cancers, particularly in the supra glottis. Less than 1% of patients with
LSCC are asymptomatic at presentation 1. 
As  the  sensitivity  of  the  most  frequently  used  diagnostic  procedures, 
though relatively high, is not absolute 97% for direct  laryngoscopy, 90% for 
indirect  laryngoscopy, 80% for CT of the primary site  1,  a number of LSCC 
patients may escape the first diagnostic approach. For most of its natural course, 
LSCC is clinically silent and even histologically occult, so no current protocols 
for clinical screening can sufficiently anticipate tumor detection.
             The clinical TNM often underestimates the extension of the disease 
when compared with the real pathological TNM, which places a significantly 
higher proportion of tumors in the advanced-stage (III or IV) group  1. Clinical 
methods  are  inaccurate  predictors  of  pathological  findings  and  may 
underestimate disease extension and macroscopically uncertain margins.  
Therefore, the TNM cannot be adequately evaluated in patients treated 
exclusively  by  radiotherapy,  in  the  absence  of  a  surgical  specimen.  After 
irradiation, it can become very difficult to assess data obtained by imaging and 
endoscopy  for  the  diagnosis  of  both  minimal  residual  disease  and  early 
recurrence.  
            Despite the multiplicity of clinical prognosticators, the only consistent  
clinical predictors for disease control and disease-specific survival in LSCC are 
T and, to a greater extent, N. 7,8,11.
 The prognostic stratification of LSCC patients is inadequate since similar 
patients,  affected  by  tumors  with  similar  clinico  pathological  features  and 
undergoing the same treatment, may differ widely in prognosis, probably due to 
the extreme biological heterogeneity of LSCC, which contributes to the lack of 
consistency in treatment planning. 
So  a  different  approach  to  LSCC,  based  on  genetics  and  molecular 
biology  in  addition  to  the  clinical  and  histological  approach,  is  required  to 
overcome  these  obstacles  and  to  reduce  cancer-related  mortality  in  LSCC 
patients.
1.1 Potential clinical application of molecular markers
 Although the best-known risk factors, clinical TNM and histopathological 
grading  will  retain  their  value,  it  is  now  possible  to  acquire  biological 
information about host and tumor to optimize the management of LSCC. 
Systematic study of biological markers might be integrated into clinical 
practice in the phases of prevention as ‘molecular epidemiology’ of diagnosis as 
‘molecular  diagnostics’,  of  prognostic  assessment  and treatment  selection as 
‘molecular characterization’ 12 , and of  the synthesis of new drugs as  ‘molecular 
targeting’.  
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1.2 Molecular epidemiology 
The best-established risk factors for LSCC are behavioral, e.g. cigarette 
smoking  and  heavy  drinking.  Primary  prevention  can  be  easily  obtained  by 
abandoning  adverse  habits,  but  not  all  LSCC  patients  have  a  history  of 
behavioral risk factors or clinically evident precancerous lesions.
Molecular epidemiology should help us to recognize patients and/or areas 
of  laryngeal  mucosa  with  a  high  susceptibility  for  developing  LSCC,  and 
possibly  to  identify  molecular  targets  for  effective  secondary  prevention 
(chemoprevention).
  The incidence of genetic alterations in dysplastic, pre malignant lesions is 
greater  than  half  that  found  in  invasive  HNSCC  13.   The  latency  between 
carcinogen exposure and the appearance of malignancy may be as long as 25 
years,  so  important  molecular  alterations  should  be  detectable  in  affected 
mucosa many years before an invasive phenotype is produced, and presumably 
some  of  these  will  be  more  strongly  associated  with  progression   toward 
carcinoma.
 Several  cellular  alterations  have  been  tested  in  clinical  studies  as 
potential markers of commitment to transformation (molecular histopathology), 
both in pre malignant lesions and in apparently healthy mucosa 14-17. Markers of 
commitment could help in the early diagnosis of malignant transformation by 
stringent  follow  up  of  high-risk  mucosal  areas  and  in  timely  secondary 
prevention by immediately evaluating its effects at the molecular level 15.
             The p53 pathway is of great interest in this aim.  p53 is normally  
expressed in LSCC more frequently and the p53 gene has a mutation pattern 
more similar to that in lung SCC than in other HNSCC  4  .Alterations in p53 
status have been extensively studied in tumor cells, in precancerous lesions and 
in apparently healthy mucosa of HNSCC patients, in the hope of verifying the 
intriguing hypothesis that they might predict the development of SCC  18,  18-20. 
Mutations of p53 have also been evaluated to establish whether multiple primary 
tumors have a mono- or polyclonal origin21, 22. 
Although  no  definitive  conclusions  have  yet  been  drawn  about  these 
fundamental issues, a coherent model is now beginning to emerge 23 and the use 
of  p53  alterations  as  a  marker  to  identify  ‘condemned  mucosa’  remains  an 
intriguing, if still   hypothetical, possibility.
 In  LSCC,  p53  expression  is  altered  less  frequently,  with  a  mutation 
pattern different from that of other HNSCCs (and more similar to lung SCC) 4. If 
we assume that the p53 pathway is impaired in some way in every malignant 
epithelial  neoplasm,  then  alternative  mechanisms  of  inactivation  could  be 
particularly relevant in LSCC 4.
             Degradation mediated by other cellular proteins, such as mdm2 24, or by 
human  papilloma  virus  (HPV)  E6  oncoprotein  25, may  represent  two  such 
alternative pathways leading to loss of p53 function. Chromosomal alterations, 
such  as  9  p21  loss,  are  prevalent  and  early  events  in  carcinogenesis,  and 
proposed targets for preventive strategies 13, 15. 
            The over expression of the epidermal growth factor receptor (EGFR) 14, 
alterations  in  Cyclin  D1  (in  the  earliest  phases,  over  expression,  and  later 
CCND1 amplification) 14, 26    and high telomerase activity 27 are early events, and 
may be potential markers for the prediction of neoplastic progression. Individual 
susceptibility  to  LSCC may derive  from environmental  or  genetic  factors.  A 
genetic predisposition to the development of LSCC is highly probable. 
    
 Intrinsic  sensitivity  of  cells  to  mutagens  such  as  bleomycin  is  a 
biomarker  of  HNSCC  susceptibility  28. Polymorphisms  of  carcinogen, 
metabolising enzymes known to be involved in the metabolism of carcinogens 
found in tobacco smoke are relatively common in most populations.  
A  growing  body  of  evidence  suggests  that  many  of  these  genetic 
polymorphisms are associated with the risk of developing cancers of the aero 
digestive tract 29-31.
In particular, the risk of developing LSCC has been evaluated in relation 
to  polymorphisms of  genes  encoding for  aryl  amine N-acetyl  transferases  32, 
human OGG1 DNA repair enzyme 33, CYP1A1, XRCC 31   and glutathione S-
transferases, with controversial results 35, 36. 
These  and other  detoxifying  enzyme genes  might  be  evaluated  in  the 
future to assess susceptibility to environmental carcinogens and thus the risk of 
developing LSCC in association with tobacco smoking.
1.3 Molecular diagnostics
Molecular diagnostics should help us to:
1. Diagnose biological transformation, even with negative histology;
2. Detect extremely early neck node involvement (occult metastases);
3. Assess precisely, even in the absence of surgical specimens, the local and 
regional spread of the tumor;  
4. Detect minimal residual disease at the margins of surgical resection and at the 
primary site after irradiation;
5. Diagnose extremely early recurrences. 
The clinical goals of molecular diagnostics are earlier, initial or salvage 
treatment and safer oncological effectiveness with better functional results. The 
detection of minimal residual disease and of early recurrences and metastases by 
molecular  markers  would  be  particularly  useful  after  radiotherapy,  when for 
several  months  radiation  damage  makes  the  evaluation  of  treated  sites  more 
difficult, often with fatal diagnostic delay. 
Histopathologically benign mucosa of the upper aero digestive tract may 
harbor foci of clonal, preneoplastic cells that are the site of origin of genetically 
related, metastatic HNSCC. The use of multiple biopsies aiming to map, for 
example by micro satellite analysis, the mucosal sites that harbor these clones 
may be a useful tool 6.
The  perfect  marker  for  molecular  diagnostics  should be present  in  all 
LSCCs, easily detectable even in histologically occult cases (high sensitivity), 
indicative of non-reversible passage from severe dysplasia to cancer (capable of 
differentiating  precancerous  lesions  from  early  carcinomas)  and  thus  always 
absent  in  non-cancerous mucosa (high  specificity).No biological  marker  with 
these characteristics has yet been described; all molecular features proposed so 
far only approximate such an ideal.  
One of these is  eIF4E over  expression,  which can be demonstrated in 
practically all LSCCs and whose presence in histologically tumor-free surgical 
margins predicts recurrence with discrete specificity and good sensitivity 68.Loss 
of  p16  expression  is  one  of  the  most  frequent  molecular  abnormalities  in 
HNSCC  69 and  seems  be  important  in  laryngeal  carcinogenesis  70,  71, but  its 
clinical potential in LSCC requires further evaluation. p53 mutations appear to 
predict  local  recurrence  when  detected  on  surgical  resection  margins  72.An 
alternative cytogenetic approach has been proposed by Califano et al. 13.
1.4 Molecular characterization
            Molecular characterization by the study of predictive molecular factors 
aims to define homogeneous groups of patients for prognostic stratification and 
treatment selection. Although a plethora of studies have sought to evaluate their 
potential, no molecular marker yet contributes to clinical decision-making. 
 
             Attempts have been made to   outline how molecular markers might be 
integrated  with  standard  TNM and  histological  grading  (clinico  pathological 
parameters). The perfect marker for molecular characterization of LSCC should 
not  be  constantly  present  in  malignant  cells  but  invariably  associated  with 
precise biological features and predictable clinical behavior, and easily detected 
by  a  standard,  reliable  and  simple  assay  on a  small  sample  such  as  from a 
biopsy. No such marker yet exists. 
          Recently, cDNA micro arrays, a powerful tool from which large amounts  
of genetic information can be obtained, have been used for an initial tentative 
molecular classification in HNSCC, based on patterns of global  gene expression 
73,74. This  method  can  only  be  applied  to  frozen  tissues,  because  RNA  is 
destroyed during formalin fixation, and a frozen tumor bank combined with a 
strong clinical database and complex statistical capacity would be required to 
make full use of this expensive technology. 
 Searching for  three or  four well-defined biological  markers with more 
reliable assays might allow us to classify tumors as positive (Mc+) or negative 
(Mc-) for molecular characterization. We should try to assess at least some of the 
main biological features of tumors, such as aggressiveness, invasiveness, radio, 
and chemo sensitivity.  .  These characteristics, intrinsic to a given tumor and 
also    some  of  the  molecular  markers  studied    have  a  large  influence  on 
prognosis and should guide therapeutic decisions. 
TNM staging  could  then  become  TNMMc staging,  resulting  in  better 
prognostic  stratification  of  patients  and  the  selection  of  the  most  suitable, 
individualized treatment. It would prevent the over treatment of Mc-ve patients 
and, most importantly, the under treatment of Mc+ patients, which has probably 
contributed to the cited failure to improve prognosis in LSCC over the last 30 
years.
          In Mc+ tumors, larger resection margins could be planned with a more 
ablative approach to primary tumor, since conservative surgery is too risky in 
these  cases.  In  cN0 patients,  a  more aggressive approach in  the  neck would 
involve elective bilateral dissection or elective irradiation. 
Adjuvant radiotherapy could be advised also in tumors with histologically 
negative resection margins.In Mc –ve   tumors; integrated staging might allow 
safe  indications  for  conservative  surgery  and thereby functional  preservation, 
lowering at the same time the risk of failures.  
 1.5 Characterizing molecular markers
Among the markers evaluated so far, some have appeared potentially 
reliable and suitable from a clinical perspective.
i. Epidermal growth factor receptor (EGFR)        
     
There is strong evidence of a role for EGFR expression (and, to a lesser 
extent,  for  its  ligand,  transforming  growth  factor-a)  in  predicting  prognosis, 
because it adversely influences overall relapse-free and metastasis-free survival 
in LSCC. 
EGFR  retains  a  strong  predictive  value  independently  of  treatment 
(surgery, chemotherapy and radiation)  75-80, which makes it,   the most reliable 
prognostic  molecular  marker  at  present.  Furthermore,  EGFR over  expression 
seems to predict both chemo- and radio resistance 79, 81.
 It is a receptor for growth factors (as TGF and EGF) with tyrosine kinase 
activity in normal cells.  Upstream activator of MAP kinase pathway and  of 
other pathways involved in cell growth, cell migration, block of apoptosis. It is 
frequently  and  early  over  expressed  in  LSCC,  mainly  by  post-translational 
mechanisms.  At  present  the  most  reliable  biological  marker  for  molecular 
characterization, marker of aggressiveness 75, 76 and of invasiveness 77.
ii. p53
 Alterations of p53 protein expression and mutations of the p53 gene have 
been extensively studied as predictors; changes in p53 are proposed independent 
predictors of recurrence in LSCC  24,82, but this prognostic value is controversial4 
, especially in surgically treated   patients 83.
p53 over expression, detected by immunohistochemistry (IHC) in an high 
percentage of LSCC  84, appeared to correlate well with p53 mutation  85,but a 
recent  study  has  shown  significant  discrepancies  between  p53  IHC  and 
genotyping data 86 .
 p53 gene mutation has been suggested as more reliable than IHC over 
expression  for  characterization  and  reportedly  predicts  the  response  to 
radiotherapy  in  LSCC  patients  86; this  observation  is  consistent  with  the 
biological role of p53, which mediates apoptosis associated with DNA damage.
iii. CYCLIN D 1
                   A separate prognostic role has been described for Cyclin D1 protein  
over expression 87 and CCND1 gene amplification 88, with an impact on relapse-
free  and  overall  survival  in  HNSCC.  Studies  on  breast  tumors  and  also  on 
HNSCC  have  shown  that  CCND1  amplification,  rather  than  protein  over 
expression, might have prognostic value 119. 
iv. Over expression and amplification of Cyclin D1 gene (CCND1)
                 Cyclin D1 gene transcriptional activity normally strictly depends on  
mitogen stimulation, and leads to cell commitment to mitosis through START 
checkpoint.  An  early  CCND1  over  expression  is  often  detectable  without 
evidence of gene amplification; it can be used for molecular epidemiology but it 
seems  to  retain  a  lower  prognostic  value,  if  compared  with  CCND1 
amplification, a marker of aggressiveness in LSCC 88.
        The cyclin D1 gene plays a pivotal role in the regulation of the cell 
cycle89. During the middle to late G1phase90, it complexes with cdk4 or cdk6, 
thus  promoting  the  phosphorylation  of  the  pRb  gene  product  and,  finally, 
progression to the S phase91.
It has been shown that cyclin D1 can become deregulated as a result of 
various genetic lesions, including chromosomal inversion and translocation in 
parathyroid  adenomas  and  B-cell  non-Hodgkin  lymphomas  92,  93 or  gene 
amplification in carcinomas of the breast 94, 95 liver96 pancreas 97 esophagus 98anus 
98ovary99bladder 100 and lung 101
 Experimental observations indicate that a moderate over expression of 
Cyclin D 1 leads to a shortening of the G1 phase and less dependence on growth 
factors for cell proliferation.  102,103 .It has likewise also been recently reported 
that  antisense  to  Cyclin  D  1 is  capable  of  inhibiting  the  growth  and 
tumorigenicity of human colon cancer cells, which thus suggests that increased 
cyclin D1 expression might contribute to the abnormal growth of tumor cells104
Cyclin Dl gene aberrations are frequently detectable in head and neck 
tumors105-110, 88,111-113 especially in carcinomas of the hypopharynx and, to a lesser 
extent, in those of the oropharynx and larynx114-116 
  It  has  been  reported  that  Cyclin  D  1  amplification  and/or  over 
expression  are  associated  with  unfavorable  clinico  pathologic  features114,  116 
tumor recurrence, and a poor prognosis111, 115,117,118
v. Telomerase activity
                   In a normal cell a low telomerase activity, required for telomere  
lengthening  and  autonomous  replication,  can  be  detected  in  haematopoietic 
tissue, in some  immune cells (activated lymphocytes), in basal epithelial layers. 
Absent in most non-transformed differentiated cells. 
                   It is present, often at high levels, in most laryngeal cancer cells. It  
can  at  least  partly  depend on h-TERT gene  (coding for  catalytic  subunit  of 
telomerase) over expression 27.
          
vi. Cathepsin D
                  It is a Lytic enzyme active in extra cellular matrix rearrangement. An 
over expression is often detectable in tumor cells, where it seems to contribute to 
invasiveness 119.
 
vii. Human papillomavirus (HPV)
                 Normally absent in cells, HPV affect epithelia with mucosal or 
epidermal  tropism  according  to  genotype.  In  tumor  cells  important  onco 
suppressors  such  as  p53  and  pRb  are  inhibited  and  degraded  by  HPV 
oncoproteins. In turn, over expression of Oncogenes such as EGFR and Cyclins 
A and B is induced 40, 51-53.
viii. Type II oestrogenbinding sites (EBS)
These are normally present in laryngeal mucosa.  Type II EBS may at 
least  partly  mediate  tumor  growth  inhibition  by  tamoxifen  and  quercetin; 
possible targets for chemoprevention and therapy 122.
ix. S100-A2 Ca2+ binding protein
Increasing  levels  of  expression  during  differentiation  of  squamous 
epithelial  cells;  absent  in  basal  layers.  Under  expression  in  cancer  cells,  are 
inversely proportional to tumor differentiation. Starting from data on NSCLC a 
role as a real oncosuppressor has been hypothesized 121.
 
x. Methyl-p- hydroxyphenyllactate esterase (MEPHLase) activity
Enzyme involved in the metabolism of methyl-p- hydroxyl phenyl lactate,
ligand of type II EBS, with a role in growth and differentiation of several tissues 
(breast,  uterus),  normally  expressed  in  larynx.  In  LSCC  a  low  activity  is 
associated with poor differentiation, and shorter overall survival and metastasis-
free survival 123.
xi. Type 2 cyclo-oxygenase (Cox-2)
Enzyme involved in arachidonic acid metabolism and autacoid synthesis, 
induced by various stimuli in several cell types. Cox-2 activity seems to promote 
tumor  neo  angiogenesis.  Nevertheless,  evidence  exists  that  low  Cox-2 
expression  indicates  poor  differentiation  and  higher  aggressiveness  and 
invasiveness 61.
 
xii. Galectin-3
                Galectin-3 is a pleiotropic carbohydrate-binding protein participating 
in a variety of cell processes, and mediating cell-to-cell interactions.Galectin-3 
expression seems positively associated with tumor keratinisation and histological 
grade. A significant correlation was found between galectin-3 tumor positivity 
and longer metastasis-free and overall survival in LSCC patients 120.
 Various problems affect the clinical application of molecular markers for 
tumor  characterization.  The  perfect  marker  has  yet  to  be  demonstrated;  in 
particular  the  detection  assays  must  be  practical  and reliable,  and should  be 
widely available. 
The inconsistency of assay methods for most factors studied, and patient 
and  treatment  heterogeneity,  all  detract  from  an  ability  to  draw  definitive 
conclusions. Meta-analysis of published data and by multidisciplinary and multi 
centre clinical trials is needed to evaluate every molecular marker proposed for 
clinical practice. 
1.6 Objectives of the study
1. To analyze the expression of Cyclin D 1 – a cell cycle regulatory    protein, in 
squamous cell carcinoma of larynx patients
2.  To  correlate  the  expression  of  Cyclin  D1  with  clinical  and  pathological 
parameters like Age of the patient, Extent of tumor and Nodal status, Grade and 
Stage of the tumor, any predilection for sub sites in the larynx.
3. To investigate whether over expression of Cyclin D 1 is associated with an 
increased likelihood of tumor recurrence   and over expression of Cyclin D 1 
could serve to identify a proportionally distinctive group of patients.
1.7 Scope of the study
On the basis of these immuno histochemical results, it was possible to 
select a subgroup of patients with a high risk of recurrence and poor prognosis to 
undergo  more  extended  surgical  treatment  and/or  combination  anti  tumoral 
therapeutic procedures. 
 
The  goal  is  to  block  specific  pathways  involved  in  the  carcinogenic 
process or in tumor pathogenicity (aggressiveness, invasiveness), and to restore 
effective oncosuppression and possibly in the treatment (Antisense Cyclin D 1)
CHAPTER 2
MATERIALS AND METHODS
2.1 Materials 
The retrospective study group consisted of   74 patients with squamous 
cell  carcinoma of  larynx treated in  Cancer  Institute  (WIA),  between January 
2000 and December 2003.
These patients were selected randomly based on the inclusion criteria:
1. No history of previous malignancy
2. Primary squamous cell carcinoma of larynx only
3. Not received any treatment before  
Samples for histopathological examination were obtained prior to starting 
the appropriate therapy.
71  patients  were  male  and  3  were  females.  Clinical  staging  and 
identification  of  the  anatomical  site  of  the  tumors  were  based  on  the 
International  Union Against  Cancer  (UICC) TNM classification of malignant 
tumors. 
15 of them (20.3%) were supra glottic, 47 (63.5%) were glottic and 12 
(16.2%) were transglottic  tumors.  Grade of  differentiation of the tumor were 
made according to Broder’s classification. 7 well differentiated, 25 moderately 
differentiated and 35 poorly differentiated tumors were studied. For 7 tumors 
grade was not known. 
Depending on the stage of the disease these patients were treated with 
primary  radiotherapy;  primary  surgery  and  combination  of  radiotherapy  and 
surgery. 
2.2 Methods
Expression of Cyclin D1 was studied immuno histochemically and the 
primary antibody used was Monoclonal Mouse Anti  human Cyclin D1 clone 
DCS 6 (DAKO cytomation Denmark)
The samples from all of the cases were routinely fixed in 10% buffered 
formalin and embedded in paraffin. The paraffin embedded section of 5 micron 
thick was placed on 3’Amino Propyl Triethoxy Selaine (APES) coated slides.
Positive and negative controls were used. Positive control was taken from 
a carcinoma larynx specimen found to have expressing Cyclin D 1. Same was 
used as negative control but   Cyclin D 1 antibody was not added.
 The slides were treated in Xylene consecutively twice for 8 minutes, to de 
wax  the  sections  and  this  was  followed  by  treatment  with  absolute  alcohol 
consecutively twice for 5 minutes to dehydrate them.
Slides were washed in tap water for 8 to 10 minutes taking care not to 
disturb the tissue sections and then the slides were placed in 0.3 % hydrogen 
peroxide for 30 minutes, to quench endogenous peroxidase activity in the tissues 
2.2.1 Antigen retrieval 
Antigen  retrieval  is  needed  for  exposure  of  the  epitopes  for  immune 
reaction. The slides which were quenched of peroxides were wet autoclaved at 
121 degree Celsius in 10 mM citrate buffer at pH 6 for antigen retrieval and no 
holding time is required for it .The autoclaved slides were cooled and washed 
with Phosphate buffered saline (PBS) for 5 minutes.
2.2.2 Blocking antibody reaction
The slides were arranged on a moist chamber to prevent drying of the 
sections. 100 micro liters of 2 % BSA (Bovine Serum Albumin) was added to 
each section, taking care to cover the whole section and left undisturbed for 30 
minutes. 
Following gentle tipping of BSA off the slides, 75 microlitre of primary 
antibody (cyclin D1) was added to each section in 1: 75 dilutions. Care was 
taken to omit the negative control. 
The  slides  were  left  overnight  undisturbed  to  incubate  with  primary 
antibody at 4 – 8 degree Celsius in a refrigerator and on the next day, the slides 
were washed with PBS thrice for  5 minutes each,  to wash off  the excess of 
primary antibody. 
2.2.3 Secondary antibody
Secondary antibody (Rabbit anti mouse) was added in 1: 300 dilutions to 
the slides and incubated for 35 minutes in room temperature. The slides were 
washed  in  PBS  thrice  for  5  minutes  each  and  then  ABC  (Avidin  Biotin 
Complex) 75 micro litre was added to each slide and incubated for 30 minutes. 
Throughout the procedure care was taken not to dry up the slides completely.
2.2.4 Treatment with chromogen
Slides were washed in PBS thrice for 5 minutes each, to wash off the 
excess of ABC and were treated in a solution of DAB (Di Amino benzidine + 
150 ml of water + 150 ml PBS + 100 µl of Hydrogen peroxide) for 5 minutes. 
The excess of DAB was washed off the slides in tap water for 5 to 10 minutes  
and counterstained in hematoxylene for 2 minutes. 
The slides were washed for 5 to 10 minutes in water and fixed in lithium 
carbonate  saturated  solution  and  washed  under  tap  water  once  again  for  5 
minutes. The slides were drained well and treated with absolute alcohol twice for 
3 minutes each followed by treatment in Xylene twice for 5 minutes each. Then 
sections were mounted using DPX.
2.2.5 Pathological analysis of expression of Cyclin D 1  
Immuno histochemical staining was scored by a pathologist who is not 
aware of the clinical  details.  Whole of the microscopic fields of the sections 
stained were studied for scoring with 40 X magnification.
 Scores were ranked as, 87,107,181
-      Negative; 
+/-   0-5% tumor cells were positive; 
+     5-50% tumor cells were positive;
++   >50% tumor cells were positive; 
Only nuclear staining was taken into account              
                                                                                                           
2.3 Statistical Analysis
Descriptive statistics were calculated with their 95% confidence intervals. 
Associations between clinico pathologic and immuno histochemical results were 
evaluated by means of ‘Chi Square Test’.
 For the purpose of statistical analysis Cyclin D1 was considered in two 
classes: Positive  (> 5% tumor cells were positive for Cyclin D 1 expression) and 
Negative ( No expression of Cyclin D 1 or < 5% tumor cells were positive for 
Cyclin D 1). 
Other investigated prognostic factors were classified as follows—
Age at diagnosis: <30 years,  31-40, 41-50,  51-60,  61-70,  71-80; Histological 
grade:  G1,  G2,  G3and Gx ;  Lymph node  metastasis:  Positive  and Negative; 
Tumor extension T1a, T1b, T2-4, Clinical stages: Stage I and II together and 
Stage III and IV together.
 Finally distribution of Mean and standard Deviation of time to recurrence 
and Cyclin D 1 expression ; distribution of Mean and standard Deviation of time 
to residual disease after treatment with Radiotherapy and Cyclin D 1 expression 
was studied. 
CHAPTER 3
REVIEW OF LITREATURE
3.1 Laryngeal cancer 
3.1.1 Epidemiology
Cancer of the larynx is  one of the most common cancers seen among 
male.  It  ranked  within  the  top  ten  cancers  in  males  and  accounts  for 
approximately 4.1% of all male cancers according to our hospital based cancer 
registry (1998-2002)124.  The larynx is the second most common site of cancer in 
the upper aero digestive tract, preceded in frequency only by the oral cavity.
It is one of the few cancers, which has a high male predominance. The 
average number of cases per year is about 9 fold higher among males in the ratio 
of 108 females to 1000 males, but recent data show that the ratio of affected 
males to females is decreasing as the result of an increasing incidence among 
women2. 
Squamous  cell  carcinoma  accounts  for  greater  than  95% of  laryngeal 
cancers 124. Glottic and supraglottic larynx are the common sub sites in laryngeal 
cancer. Women are more likely to develop supraglottic cancer than glottic125.
The distribution by subsite revelaed that a majority of cases had a Glottic 
involvement  (41%)  followed  by  Supraglottis(27%).  27%  of  cases  not 
categorized by subsite126.
At  cancer  institute  the  tumor  stage  data  among all  cases  revealed  the 
following: Stage I (25%), stage II (15%), stage III (33%) and stage IV (23%); 
stage unknown was 4 %. A slightly less than half of the total cases registered at  
Cancer  Institute  received  cancer  directed  treated  with  the  radiation  therapy, 
either alone or in combination with other modalities, forming the majority126
 Cancer of the larynx is a disease of the elderly, with the peak incidence 
in the sixth and seventh decades 124,127. Less than 1% occurs below the age of 30 
years 124, 128. No racial predominance has been demonstrated.
 The  estimated  5  year  survival  for  cancer  of  the  larynx  as  a  whole, 
including all  stages is 68% making it  one of the more curable cancers of the 
upper aero digestive tract. However this numbers has not changed significantly 
over, at least, the last 20 years129. According to our institute data the overall and 
disease  free  survival  from  laryngeal  cancers  treated  in  1997  and  followed 
through 2002 were 52% and 50% respectively.126
             
In Europe laryngeal squamous cell carcinoma is one of the most frequent 
malignancies of Head and Neck region, accounting for about 52,000 new cases 
per  year130.  The  yearly  incidence  rate  for  men  in  Northern  Europe  is 
approximately  6  per  100,000,  rising  until  18  per  100,000  in  Southern 
countries131.
               In the United States laryngeal squamous cell carcinoma is estimated to 
account for almost 0.8 % of all new cases of malignancy, with an incidence of 
10,000 cases per year, and to have caused 0.6% of all cancer deaths in 20042. 
Most of these tumors originate in the glottis or supra glottis; the sub glottis is an 
extremely rare site of origin132.
3.1.6 Etiology
              As with most tumors, multiple factors contribute to the development of  
cancer of the larynx. Foremost among them is tobacco. Second is the synergistic 
effect produced when tobacco is combined with heavy alcohol intake. 
Risks were also shown to decline markedly with risk returning to nearly 
that of non smokers by 15 years after cessation133. Alcohol is an independent risk 
factor only for cancers of the supraglottic larynx134.
           
             Certain occupations and exposures also pose a higher risk for subsequent 
cancer  of  the  larynx.  Painters,  metal-working  and  plastic-working  machine 
operators,  construction  workers  and  those  exposed  to  diesel  and  gasoline 
fumes135, 136 as well as those exposed to therapeutic does of radiation 137.
            Dietary factors – A protective effect has been demonstrated for fruits and 
dark green vegetables possibly due to their high concentration of carotenoids138. 
Salt preserved meats and high dietary fats have been implicated in increasing the 
risk for cancer of the larynx139.
           The incidence of genetic alterations in dysplastic, pre malignant lesions is 
greater  than  half  that  found  in  invasive  Head  and  Neck  Squamous  cell 
carcinoma13.   The latency between carcinogen and the appearance of malignancy 
may  be  as  long  as  25  years,  so  important  molecular  alterations  should  be 
detectable  in  affected  mucosa  many  years  before  an  invasive  phenotype  is 
produced and presumably some of these will be more strongly associated with 
progression toward carcinoma14.
           The p53 pathway is of great interest in this aim. Alterations in p53 status 
have  been  extensively  studied  in  tumor  cells,  in  precancerous  lesion  and  in 
apparently  healthy  mucosa  of  HNSCC patients,  in  the  hope  of  verifying  the 
intriguing hypothesis that they might predict the development of SCC. 
Use of p53 alterations as a marker to identify condemned mucosa remains 
as  intriguing,  if  still  hypothetical  possibility18,  140.  In  laryngeal  cancer,  p53 
expression is altered less frequently, with a mutation pattern different from that 
of others HNSCCs (and more similar to lung SCC) 141. 
Chromosomal  alterations,  such  as  9p21  loss,  are  prevalent  and  early 
events in carcinogenesis, and proposed targets for preventive strategies26.  The 
over  expression  of  epidermal  growth factor  receptor  (EGFR)  14,  alteration  in 
Cyclin  D  1(in  the  earliest  phases,over  expression  and  later  CCND1 
amplification) 142  and  high  telomerase  activity  are  early  events  any  may  be 
potential markers for the prediction of neoplastic progression.
3.1.7 Diagnosis 
      The three modalities used to evaluate cancer of the larynx, as with all upper 
aero digestive lesions, are history and physical  examination, radiography and 
endoscopy. 
A history of gradual development of hoarseness, sore throat, dysphagia 
and odynophagia  are  common presenting  symptoms.  Hoarseness  is  produced 
early  in  cancer  of  the  glottis  but  is  a  late  finding  in  carcinomas  of  the 
supraglottic and subglottic larynx.
Video laryngoscopy allows documentation of the size and extent of the 
cancer of cancer at presentation and assists with planning operative approaches, 
especially when conservation laryngeal surgery is anticipated. 
In  cancers  of  the  supraglottis,  involvement of  the  pre-epiglottic  space, 
paraglottic space, pyriform sinus or arytenoids will often have a major impact on 
treatment.  For  cancers  of  the  glottis,  involvement  of  anterior  commisure, 
ventricle, paraglottic space or subglottic larynx will have a similar impact on the 
treatment chosen. 
For  cancers  of  the  subglottis,  the  extent  of  tracheal  and  esophageal 
involvement  must  be  known  in  order  to  prepare  for  appropriate  surgical 
reconstruction or adequate radiation portals. It is in the assessment of these key 
areas, often hidden from physical examination, that radiography and operative 
endoscopy are invaluable.143
3.1.8 Prognosis 
            Multiple studies have shown that increasing T stage and increasing N 
stage correlate  independently  with lower survival,  and that  for  cancer  of  the 
larynx, N stage is more predictive of overall survival than T stage144. 
Extra capsular spread outside the involved lymph nodes also portends a 
poor prognosis145. Overall low patient performance status and presence of nodal 
metastasis in the inferior aspect of neck (level IV) 146 are other clinical factors 
associated with a decreased survival from cancer of the larynx. 
Tracheostomy prior  to  definitive  treatment  of  an  obstructing  laryngeal 
cancer  has  been shown in  several  studies  to  have  an  increased  incidence  of 
stomal  recurrence  and  decreased  overall  survival147,  148.  Peri  neural  and 
perivascular invasion both indicate aggressive cancer behavior. The influence of 
histologic grade of the primary cancer is not certain. 
Squamous cells carcinomas are graded into poorly, moderately and well 
differentiated  neoplasms  based  on  their  keratinization  and  nuclear  atypia9. 
Generally, well differentiated carcinoma grows in a bulky rather than infiltrative 
pattern  and  remains  localized  for  longer  periods  of  time  than  poorly 
differentiated cancer.
3.1.9 Treatment 
 The treatment of cancer of the larynx has evolved significantly over the 
last two decades. The standard options for treatment of Laryngeal carcinoma are 
surgery, radiotherapy, chemotherapy or a combination of these. Radiotherapy is 
used in more than 70% of patients, surgery in about 55% and chemotherapy in 
10%149. 
It  is  widely  accepted  that  most  early  stage  Laryngeal  cancers  can  be 
adequately treated with single modality therapy, whether surgery or irradiation, 
with a 5 year local control of 85-98%.150.  A multimodality approach based upon 
a combination of surgery and irradiation is the most common treatment for stage 
III and IV disease132.
 The development  of  oncologically  sound conservation procedures  has 
allowed  more  patients  to  retain  airway  and  voice  in  early  cancers.  The 
refinement  of  radiation  therapy  techniques,  potentially  augmented  by  the 
addition of chemotherapy has allowed similar organ preservation with advanced 
cancers. 
These  improvements,  however  have  not  translated  into  significantly 
improved survival rates. Perhaps with an ever-increasing understanding of tumor 
biology  and  biologic  response  modifiers,  immunotherapy  may  play  a  more 
prominent role in preventing the growth, spread and even the development of 
carcinomas.
3.2 Cell cycle 
3.2.1 Basic concepts 
The biology of cell division, differentiation and apoptosis is exceedingly 
similar in both normal and cancer cells. The cancer cell differs from its normal 
counterpart in that it is aberrantly regulated. 
            Cancer cells generally contain the full complement of bio molecules that  
are  necessary  for  survival,  proliferation,  differentiation,  cell  death  and 
expression  of  many  cell  type-specific  functions.  Failure  to  regulate  these 
functions properly, however, results in an altered phenotype and cancer.
Four cellular functions tend to be inappropriately regulated in a neoplasm. 
First, the normal constraints on cellular proliferation are ineffective. Second, the 
differentiation program can be distorted. The tumor cells may be blocked at a 
particular stage of differentiation or they may differentiate into an inappropriate 
or abnormal cell type.
 Third, chromosomal and genetic organization may be destabilized such 
that variant cells arise with high frequency; some variants may have increased 
motility or enzyme production that permits invasion and metastasis. Finally the 
tightly regulated cell death program (apoptosis) may be deregulated151
             Cell division cycle can be divided into two functional phases- S and M 
phases, and two preparatory phases- G 1 and G 2. S phase is defined as the 
phase in which the DNA is replicated. The time it takes in a typical human 
cell to complete the S phase is about 8 hours and is invariant under normal 
circumstances.
Fully replicated chromosomes are segregated to each of the two daughter 
nuclei by the process of mitosis during M phase. The length of M phase is about 
1 hour and is also normally invariant. G 1 phase precedes S phase, whereas G 2 
phase precedes M phase.
G1 and G 2 phases are required for the synthesis of cellular constituents 
needed to support the following phase and ultimately to complete cell division. 
The length of G 2 phase in mammalian cells is about 2 hours. The length of the 
G 1 phase is highly variable and can range from about 6 hours to several days or 
longer. 
In human cells, the varying length of G 1 phase accounts for most of the 
differences in time it takes to execute a cell division cycle between different cell 
types growing under different  conditions.  Cells  that  persist  in G 1 phase for 
extended periods of time enter a distinct state called   G 0. 
Although  such  cells  are  metabolically  active,  they  are  not  actively 
proliferating.  Cells  in  G0 can  re-  enter  the  cell  cycle  or  can  remain  in  G0 
indefinitely.  A  successful  cell  division  cycle  requires  the  orderly  and 
unidirectional transition from one cycle phase to the next. Certain events must be 
completed before others are begun. 
In theory,  the ordering of cell  cycle events  may be accomplished in a 
manner analogous to the substrate product relationship of a metabolic pathway. 
The products of one reaction serve as the substrate for the next. The rate of first  
reaction, therefore, limits that of the next.
3.2.2 Cell cycle control
The timing and ordering of cell cycle transitions is dependent on separate 
positive and negative regulatory  circuits.  There  are two classes  of  regulatory 
circuits; Intrinsic and extrinsic152.
Intrinsic regulatory pathways are responsible for the precise ordering of 
cell cycle events. Because the length of S 1 G2 and M phases in mammalian 
cells is relatively invariant, intrinsic regulatory pathways control the transitions 
between these phases predominantly.
Extrinsic  regulatory  pathways  function  in  response  to  environmental 
conditions.  Both  types  of  regulatory  circuits  can  use  the  same  checkpoints. 
Deregulation of intrinsic regulatory pathways can contribute to cancer. 
For  example,  errors  in  the  spindle  assembly  checkpoint  can  lead  to 
chromosomal imbalance and anueploidy, a feature characteristic of virtually all 
cancers. Mis regulation of proteins that control this checkpoint has been detected 
in human cancer153, 154
Differences  between  normal  and  neoplastic  cells  are  most  commonly 
observed on the extrinsic regulatory circuits. Passage of cell cycle checkpoints 
ultimately  requires  the  activation  of  intracellular  enzymes  known  as  Cyclin 
dependent kinases (CDKs).
  CDKs exist in all  eukaryotic cells from fungi to plants to mammals. 
Activation  of  CDKs  is  the  central  event  in  cell  transitions;  their  activity  is 
exquisitely  regulated  at  several  levels155,  156.  Each  Cyclin  is  synthesized  at  a 
particular stage of the cell cycle.
3.2.3 The G 0 to S checkpoint
 The length of G 1 phase is highly variable and cells can exit the cell cycle 
for extended periods of time and mammalian cells do so during the G 1 phase of 
the cell cycle. Cells that have exited the cell cycle are said to be in G 0 state or 
quiescent. Most cells in adults are in G 0.
This absence from the cell division cycle can be temporary or permanent. 
These cells then re-enter the cell cycles,  beginning a sequence of events that 
culminates in cell division. Hence the G o / G 1 to S phase regulation are highly 
regulated and the result of this regulation, by and large determines the growth 
fraction of a population of cells.
How re-entry into the cell cycle from G 0 is ultimately controlled? 
Like other cell cycle transitions, activation of CDKs is required. G 0 cells 
are devoid of  significant CDK activity.  In  the  presence of  mitogenic  growth 
factors, expression of D type Cyclins (Cyclin D 1 D 2 D 3) is stimulated and 
continues throughout G 1 phase as long as growth factors are present157.
 D type Cyclins complex with either CDK 4 or CDK 6 catalytic subunits 
to form a holoenzyme modified by CDK activating kinase (CDK).One important 
substrate is the retinoblastoma tumor suppressor protein (Rb) and other members 
of its gene family p107 and p 130. 
Rb  is  constitutively  expressed  and  constrains  cells  from  progressing 
through the G 1 phase of the cell cycle158.On phosporylation by Cyclin D / CDK 
4 or 6, Rb loses its ability to restrain the cell cycle159. Expression of wild type Rb 
complementary DNA (cDNA) in cancer cells can inhibit their tumorigenicity160. 
Cyclin D / CDK 4 or 6 phosphorylation, which, in turn is regulated by 
p16 INK 4a, inhibits Rb function. Tumor cells that lose p 16 INK 4a or over 
express Cyclin D 1 generally retain wild type Rb. Cells lacking wild type Rb 
typically express Cyclin D 1 and p16 INK 4 a. in addition, induction of cell 
cycle  arrest  by forced expression of  p  16 INK 4 a  occurs  only in  cells  that  
contain function Rb. 
If  mutations  in  any  of  the  members  of  this  pathway  are  considered, 
disruption of this p16 INK 4a/ Cyclin D1/ CDK4 or 6/Rb pathway may occur in 
most human cancer161. Because this pathway is important for regulation of the 
G0 to S  phase  transition,  it  has  a  major  influence  of  the  growth fraction of 
normal tissues. 
Like normal cells, the transit of cell cycle check points in cancer cells 
ultimately requires the activation of CDKs. Owing to the complexity of CDK 
regulation,  defects  leading  to  inappropriate  activation  of  CDks  can  occur  at 
several levels.
The over expression of Cyclin D 1 has been detected in many human 
cancers owing to gene amplification or translocation of the Cyclin D1 gene101. 
The  Cyclin  D1 gene  is  located  on  chromosome  11  q  13.  Cyclin  D 1  gene 
aberrations  are  frequently  detectable  in  head  and  neck  tumors,  especially  in 
carcinomas  of  the  hypo pharynx and,  to  a  lesser  extent,  in  those  of  the  oro 
pharynx and larynx. 
Alterations in Cyclin D 1 (in the earliest phases,  over expression,  and 
later CCND 1 amplification) and high telomerase activity are early events in 
laryngeal cancer; these may be potential markers for the prediction of neoplastic 
progression.
 .
Cyclin D1 is a growth factor responsive Cyclin that plays an important 
role in regulating G0 /S checkpoint deregulated expression of Cyclin D1 could 
inappropriately increase Cyclin D 1/CDk 4 activities  and drive transit  of  the 
checkpoint even in the absence of appropriate growth factors. 
Direct  evidence  that  forced  expression  of  Cyclin  D  1  can  facilitate 
tumorigenisis has been obtained from transgenic mice in which over expression 
of Cyclin D1 has been targeted to the mammary epithelium. These mice develop 
ductal hyper proliferation and eventually mammary tumor formation.
Fig. 2 Factors regulating the restriction point in the G1 to S phase of the cell 
cycle
  
cdk inhibitors such as the p16ink4 family and the p21 family restrict the 
activity of cyclin-D-dependent kinases and cyclin-E dependent kinases 
respectively. Progressive Rb phosphorylation leads to liberation of active E2F to 
induce transcription of S-phase genes
3.3 Cyclins
Cyclins are a class of structurally related proteins that bind and activate 
the catalytic subunit of cyclin dependent kinases (CDKs). There are eight type of 
cyclins, ( cyclin A to H )  and all of them share an ~ 150 amino acid region of 
homology called the cyclin box whish is responsible for the CDK binding and 
activation162. 
Cyclins can be roughly divided into two subfamilies: the G 1 Cyclins and 
the mitototic Cyclins. The G1 Cyclins (C, D, E) are short lived and have rapid 
turnover throughout cell cycle, levels of transcription of their m RNA determine 
their levels. 
The mitotic Cyclins (A, B) are very stable throughout the interphase but 
undergo rapid proteolysis  by an ubiquitin  dependent pathway during mitosis. 
Compared  to  the  mitotic  Cyclins,  the  G1 Cyclins  have  a  longer  C  terminal 
sequence after Cyclin box, and it is this part of the protein that seem to confer 
instability to the G1 Cyclins.163
The function of Cyclins is primarily controlled by changes in the Cyclin 
levels,  which  increase  at  specific  stages  and are  categorized  by  the  stage  at 
which they are expressed. The G 1 Cyclins differ from the mitotic Cyclins in 
their overall primary structure and this has implications for their stability during 
the cell cycle. 
The transcription of the mitotic Cyclins, Cyclin A and B are cell cycle 
dependent  and their  levels  are  determined by transcription  and proteolysis164. 
Protein  deregulation  is  an effective  method for  promoting  unidirectional  cell 
cycle transitions because of its rapidity and irreversibility. 
Three major cell cycle transitions, entry into S phase, separation of sister 
chromatids and exit from mitosis, require the degradation of specific proteins via 
the  ubiquitination  by  26 s  proteosome pathways.  The  degradation  of  mitotic 
Cyclins  involves  the  ubiquitin  dependent  proteolytic  machinery  and  a  small 
sequence motif called the destruction box located at the N terminus. 
This region has a small cluster of conserved residues followed by a lysine 
rich stretch. The destruction box region differs between Cyclin A and B and 
probably accounts for the finding that in mitosis Cyclin A is degraded before 
Cyclin B.
G1  Cyclins  lack  the  mitotic  destruction  box  but  contain  the  PEST 
sequences  as  the  peptide  motifs  that  are  important  for  proteolysis.  PEST 
sequences (rich in proline, glutamic acid, serine and threonine) are frequently 
present in unstable proteins such as G 1 Cyclins and contain specific sites of 
phosphorylation. 
Phosphorylation  of  PEST regions  facilitates  their  destruction  of  PEST 
sequence  proteins.  Specific  motifs  within  them  actually  control  the  PEST 
sequence by the ubiquitination machinery.165 
Cyclins  are  thought  to  target  the  CDK  to  specific  substrate  and  sub 
cellular locations. Cyclin expression varies during cell cycle and the periodic 
expression of different Cyclins defines the start of each phase of the cell cycle 
and also marks the transition between the various phases.
 Cyclins and these cognate CDK catalytic subunits non-covalently form 
1:1  complexes  to  produce  the  CDK holoenzyme.  Specific  CDKs  operate  in 
distinct phases of cell cycle.
Cyclin dependent kinases 
The major transitions of the eukaryotic cell cycle are triggered be a family 
of  serine  kinases  called  the  Cyclin  dependent  kinases  (CDKs).  At  least  nine 
CDKS (CDK 1-9) are known so far166. 
CDK activation  requires  the  regulatory  subunit  called  the  cyclins  and 
phosphorylation of a conserved throenine by the CDK-activating kinase(CAK) 
which  itself  is  a  complex  of  a  regulatory  Cyclin  H and  a  catalytic  CDK 7 
subunit.
    
Fig. 3 Cyclin-dependent kinase (cdk) function in the cell cycle
D-type Cyclins (Cyclins D1, D2, and D3) activate cdk4 and cdk6 for functions 
extending from mid G1 to the G1/S-phase transition. E-type Cyclins (Cyclins E1 and 
E2) activate cdk2 for functions at the G1/S-phase boundary, probably extending into 
early S phase. Cyclin A activates cdk2 for functions extending from the G1/S-phase 
boundary and extending into G2.  Cyclin A is known to interact with cdk1 as well; 
however, no specific function for this complex has been identified. Finally, Cyclin B 
activates cdk1 at the G2/M-phase boundary with activity that lasts until Cyclin B is 
degraded during anaphase.
Cellular CDK levels  tend to  remain in  constant  excess throughout  the 
normal cell cycle and catalytic activity of CDKs is regulated post translationally. 
CDKs are closely related in size and sequence (>40% identity). 
In  human  cells,  the  growing  list  of  CDKs  includes  the  confounding 
member, CDC 2 and CDK 2- CDK 7. Our understanding of CDK structure and 
function is based largely on studies of prototypical CDKs of S. Pombe (cdc 2)  
The typical CDK catalytic unit contains 300 aminoacids. The catalytic 
subunit  is  completely  inactive  when  it  is  monomeric  and  unphosphorylated. 
Cyclins are the primary regulators of the CDKs. 
3.3.1 Cyclin dependent kinase inhibitors
The  Cyclin-CDK  complexes  are  in  turn  regulated  with  small 
inhibitory,endogenous  family  of  proteins  termed  Cyclin  dependent  kinase 
inhibitors (CKIs) that bind and inactivate CDK Cyclin complexes. Two families 
of inhibitors have been identifies in mammalian cells, with different modes of 
action. 
One group comprising related proteins namely p 21 cip1, p 27 kip 1 and p 
57 kip 2. They appear to function as broad specificity inhibitors of Cyclin/CDK 
complexes.  They associate  with  a  complex containing  a  Cyclin,  a  CDK and 
proliferating cell nuclear antigen (PCNA).
The second family of inhibitors has four members in the family p 15, p16, 
p18and p19.  These CKIs act  as  competitive  inhibitors  of  D type Cyclins  by 
forming specific complexes with the D type Cyclin partners, CDK 4 and CDK 
6.167 
Although members of the kinase inhibitor proteins were initially thought 
to exclusively regulate G1 and S phases, several reports have demonstrated that 
these proteins also regulate G2/M phase transition.
Table -1
Cyclins and cell cycle phases
Cyclin
Cell cycle phase 
Cyclin D1
Early G1 phase
Cyclin E G1/S transition
Cyclin A S phase
Cyclin B G2/M phase
Cyclin D 
The first group of Cyclins that is expressed after the cells are stimulated 
to enter the cell cycle is the D type Cyclins. D type Cyclins act as growth factor 
sensors. Cyclin D has a relatively short half-life of 20 minutes approximately 
and rapidly disappears with the removal of mitogenic stimuli or the addition of 
antiprolifetative agents. 
 Cyclin  D  complexed  with  respective  partners  CDK  4  and  CDK  6, 
participates  in  the  transduction  of  external  signals  (mitogenic  or 
antiproliferative) to other components of G1/S transition cell cycle machinery. 
Cyclin D helps in moving G0 cells into G 1 and early G 1 cells into the G 1/ S 
transition in response to the extra cellular stimuli.
The D type Cyclins belong to a distinct subset within Cyclin family based 
on structural and functional criteria. There are three genes identifies under this 
family, Cyclin D 1, D2 and D 3168.
Table -2
Cyclin D gene and chromosome locus
Gene Chromosome  Locus
CCND 1 ( cyclin D 1) 11 q 13
CCND 2 (cyclin D 2) 12 p 13
CCND 3 ( cyclin D 3) 6p 21
 
The D type Cyclins contain the sequence Leu-X-Cys –X-Glu near their 
amino terminus. This sequence is common to DNA viral oncoproteins SV 40 T 
antigen,  adenovirus  E  1  and  human  papilloma  virus  E  7  that  binds  and 
inactivates p RB and p RB related proteins. 
Fig. 4 Cyclin D regulation
  Ubiquitination of cyclin D protein is regulated by GSK3-β-mediated 
phosphorylation. Cyclin D/cdk complexes require p21, p27, and SE-1 to promote 
their assembly. Ras pathways intervene at several points to promote translation, 
transcription, assembly of complexes and the inhibition of cyclin D degradation.
The  D type  Cyclins  bind  directly  to  p  Rb  and  p  107  invitro  and  the 
interactions are disrupted by point mutations of the Leu-X-Cys –X-Glu motif. 
The oncogene-derived peptides that contain this motif compete with Cyclin D to 
bind to pRb169. 
Cyclin  D  2  and  D  3  form  more  stable  complexes  than  Cyclin  D  1 
suggestive  of  differences  in  functional  interaction  of  Cyclin  D  with  pRb 
underscores its role as a positive growth regulator with oncogenic potential.
3.3.2 p16/ pRb/Cyclin D 1 pathway
The emerging critical  role of the p16/pRb/Cyclin D 1 pathway in cell 
cycle  regulation  is  supported  by  frequent  aberrations  of  the  individual 
components of this checkpoint mechanism in human tumors. Cyclin D 1 has the 
cell  cycle  accelerating  property,  which  is  mediated  by  neutralizing  the  froth 
restraining property of p Rb via its phosphorylation. 
This function of Cyclin D1-CDK 4 complex is antagonized by p 16, the 
tumor  suppressor.  This  pathway  has  an  undisputable  biological  significance 
because the whole pathway as one functional unit I s a single complex target of 
oncogenic alterations.
Abundant evidence as been accumulated that suggests identification of a 
precise aberrant component within this pathway can have prognostic, diagnostic 
and potentially therapeutic implications.
G1  accelerating  function  of  Cyclin  D  1  and  the  growth  restraining 
function of p16 however require a functional retinoblastoma protein. Alterations 
in this pathway have been reported in non-small cell lung cancers170 and also in 
sporadic malignant melanoma.
3.4  Studies  on  Cyclin  D1 as  prognostic  marker  in  Head  and neck 
squamous cell carcinomas
p53 and Cyclin D1 as prognostic factors in squamous cell carcinoma of the 
larynx.171
  Proteins p53 and Cyclin D1 play a crucial  role  in cell  cycle  control. 
Protein p53 mutations are one of the most common genetic alterations in human 
cancer, and cyclin D1 gene amplification has been found to be associated with 
poor prognosis in different types of tumors. 
Functional alterations of these proteins may play an important role both in 
the carcinogenesis  of squamous carcinomas of the head and neck and in the 
clinical  evolution  of  these  tumors.  Presence  of  immunohistochemically 
detectable p53 is associated with shorter survival and disease-free intervals.  
Multivariate statistical analysis revealed that the accumulation of p53 is 
an independent prognostic factor, which is associated with shorter survival. This 
association was not evident in the case of Cyclin D1.  
Overexpression of Cyclin D1 indicates a poor prognosis in squamous cell 
carcinoma of the head And neck172.
  Overexpression of cyclin D1 was not associated with known 
prognostic factors (eg, the T and N stages). Tumors recurred more frequently 
and in a shorter period in patients whose primary tumors showed an over 
expression of cyclin D1 protein. This difference (P = .05) was statistically 
significant in a stepwise proportional hazard regression analysis.  .Whether over 
expression of cyclin D1 may therefore be used to select patients for more 
intensive treatment should be examined in the context of a clinical trial. 
 Prognostic significance of p53, bax and bcl-2 gene expression in patients 
with laryngeal carcinoma173.
 The expression of bcl-2 gene appears to be an independent prognostic 
factor for patients with laryngeal carcinoma. The co expression of the genes 
studied can be used to determine aggressive clinical phenotypes.   
Prognostic  significance of  expression of  p53,  bcl-2  and bax in squamous 
epithelial carcinoma of the larynx--a multivariate analysis174
  Conventional clinico pathologic parameters do not accurately reflect the 
clinical outcome of patients with head and neck carcinoma. The establishment of 
additional prognostic factors that may give insight into the biologic features of a 
tumor is therefore an essential goal.The present study analyses the expression 
patterns  of  p53,  bcl-2,  and  bax  with  regard  to  their  relationships  with 
conventional tumor parameters and to their prognostic significance in patients 
with laryngeal squamous cell carcinoma.  
  
Bcl-2  immunoreactivity  was  positively  correlated  with  an  advanced 
clinical stage, a high T category, regional lymph node metastasis, and a high 
histological  grading.  Significant  relationship  between  clinicopathologic 
parameters  and  p53  or  bax  expression  were  not  detectable.  The  age  of  the 
patients, advanced disease, positive bcl-2 expression, and a high level of p53 
expression were significantly associated with shortened disease-specific survival 
in univariate analysis.
 In  multivariate  analysis,  age,  clinical  stage,  and  p53  expression  had 
independent prognostic value. Although expression of p53 and bcl-2 was found 
to be clinically relevant in univariate analysis, only p53 but not bcl-2 was an 
independent predictor of patient outcome.
 This superiority of p53 in multivariate analysis points to its central role 
within cell cycle and death regulation, with which it influences two important 
parameters of tumor progression.  
p53, Ki67 and Cyclin D1 as prognosticators of lymph node metastases in 
laryngeal carcinoma175.
 The prognosis in patients suffering from head and neck squamous cell 
carcinomas depends on many factors. However, regional lymph node metastases 
are the most important parameter in determining the cure and survival of patients 
with head and neck cancers. 
The  evaluation  of  cancer  cell  biology  enables  differentiation  of  their 
proliferation  and tendency  of  metastases.  Immunohistochemical  examinations 
complement the well-established routine histological examination. The aim of 
this  study  was  to  evaluate  the  prognostic  importance  of  the  level  of 
immunoproliferating  proteins  such  as  Cyclin  D1,  nuclear  antigen  Ki67  and 
suppressor gene p53 for regional lymph node metastases in laryngeal carcinoma. 
 No  statistically  significant  correlation  was  found  between  staining 
intensity of suppressor gene p53, Cyclin D1 and the degree of local advancement 
(T). There was no correlation between the level of immunoproliferative markers 
and regional lymph node metastases. 
Statistically  significant  correlation  was  found  between  T  stage  and 
staining for Ki67 as well as between Cyclin D1 level and Ki67.In conclusion, (1) 
no  significant  correlation  was  found  between Ki67  and  Cyclin  D1,  p53 and 
TNM classification;  (2)  lack of  correlation was confirmed between N+, p53, 
Ki67, Cyclin D1; (3) the degree of histological grading correlated with   Cyclin 
D1 expression.  
Cyclin D1 expression is predictive of occult metastases in head and neck 
cancer patients with clinically negative cervical lymph nodes176.
 The aim of this study was to investigate the value of p53 and Cyclin D1 
gene  expression  in  predicting  the  risk  of  occult  lymph  node  metastases  in 
patients with head and neck squamous cell carcinoma. The expression of Cyclin 
D1 and p53 was evaluated by means of immunohistochemical analysis. 
This study indicates that the expression of Cyclin D1 correlates with the 
presence of occult cervical metastases in head and neck carcinoma patients, thus 
suggesting that its immunohistochemical evaluation in biopsy samples may be 
used as an additional tool for identifying patients to be treated with elective neck 
dissection .
 Image cytometry of Cyclin D1: a prognostic marker for head and neck 
squamous cell carcinomas177.
 CCND1 gene amplification and Cyclin D1 protein over expression are 
indicators for poor prognosis in invasive head and neck carcinomas. Increased 
CCND1 gene dosage is  a  more sensitive  prognostic  factor  than protein over 
expression as evaluated by conventional immunohistochemical techniques. 
Qualitative  immunohistochemistry  cannot  distinguish  Cyclin  D1  over 
expression  accompanied  by  amplification  of  the  CCND1  gene  from  over 
expression associated with normal CCND1 gene copy number. To improve the 
sensitivity of Cyclin D1 protein determination,   quantitative techniques of image 
analysis were applied to evaluate Cyclin D1 gene amplification in  head and 
neck carcinomas.    
There  was  a  significantly  higher  rate  of  occurrence  of  adverse  events 
among patients with CCND1 gene amplification than among those without gene 
amplification.  There  was  a  strong  association  between  CCND1  gene 
amplification (as detected by Southern blot  analysis)  and the highest  nuclear 
score (by image cytometry of the immunostained tumor sections).
The  predominance  of  cells  in  the  lowest  nuclear  score  category  was 
significantly  associated  with  normal  copy  number  .Conversely,  the  highest 
nuclear score was a significant predictor of gene dosage .Similarly, high nuclear 
score  was  a  good  predictor  of  death  as  the  final  outcome  of  the  disease.   
Although  somewhat  less  accurate  than  Southern  blotting,  image 
cytometry of immuno histochemical Cyclin D1 stain appears to be a promising 
tool that could be useful for other tumor marker expression studies.    
Cyclin D1 amplification and p16 (MTS1/CDK4I) deletion correlates with 
poor prognosis in head and neck tumors178.
    Cyclin D1, a cell cycle regulator localized to chromosome 11q13, is 
amplified  in  several  human  tumors  including  head  and  neck  squamous  cell 
carcinoma (HNSCC). Amplification and/or over expression of Cyclin D1 have 
been correlated to a poor prognosis. Deletion of the p16 gene, localized to 9p21, 
has also been observed in a significant proportion of HNSCC. The p16 gene 
regulates  Cyclin  D1-CDK4  activity  and  prevents  retinoblastoma  tumor 
suppressor gene phosphorylation, thereby down regulating cellular proliferation. 
FISH is a simple and sensitive method for detecting Cyclin D1 amplification and 
p16 deletion in head and neck cancer. Our results suggest that these two genetic 
aberrations together portend a poorer outcome than either of the abnormalities  
alone in head and neck cancer.  
Inactivation of p53 and amplification of cyclin D1 in squamous cell 
carcinomas of the head and neck179.
 P53 and CCND1 (Cyclin D1) genes play a critical role in the cell cycle 
regulation.  Abnormalities  of  these  genes  are  frequent  in  different  types  of 
cancers,  including  those  of  the  head  and  neck.  The  aim  of  this  work  is  to 
investigate  whether  P53  inactivation  (determined  by  loss  of  heterozygosity 
analysis)  is  related to  CCND1 gene amplification (determined by differential 
PCR analysis). No relationship was found between P53 inactivation, the clinico-
pathological  parameters  analyzed  and  the  clinical  outcome.  CCND1 
amplification was associated with advanced T-stages,  nodal metastases and a 
decreased survival. The combination of both abnormalities shows a pattern that 
seems  to  be  additive,  since  it  was  associated  with  an  increase  in  tumor 
recurrences and a decrease in survival that was higher than for either of them 
individually .
 Cyclin  D1  gene  amplification  in  human  laryngeal  squamous  cell 
carcinomas: prognostic significance and clinical implications88.
 The  Cyclin  D1  (CCND1)  gene  is  amplified,  rearranged,  and 
overexpressed frequently in human cancer, including squamous cell carcinoma. 
CCND1  amplification  did  not  correlate  with  age,  tumor  localization  and 
extension,  cervical  lymph  node  involvement,  histopathological  grading,  and 
epidermal growth factor receptor levels. 
In a univariate analysis, CCND1 amplification, tumor extension, lymph 
node involvement, poor histological differentiation, and high epidermal growth 
factor receptor levels were correlated significantly with shorter overall survival. 
In  a  multivariate  analysis,  only  CCND1  and  tumor  extension  retained 
statistically significant prognostic values. 
This is the first report in which CCND1 amplification is identified as a 
significant independent prognostic factor in laryngeal carcinoma. Evaluation of 
CCND1  amplification  could  be  applicable  to  the  clinical  management  of 
laryngeal cancer, allowing identification of patients with poor prognoses .
 
 Expression  patterns  of  Cyclins  D1,  E  in  laryngeal  epithelial  lesions: 
correlation with other cell cycle regulators (p53,  pRb, Ki-67 and PCNA) 
and clinicopathological features180.
 The expression of cell-cycle progression molecules Cyclin D1 and Cyclin 
E were immuno histochemically examined. The results of their expression were 
compared with two cell-cycle implicated tumor suppressor proteins p53 and pRb 
as  well  as  with  two proliferation  associated  indices  PCNA and Ki-67  in  an 
attempt to elucidate their potential role in the pathogenesis and progression of 
laryngeal epithelial lesions. 
High levels of Cyclin D1 and E expression were correlated with increased 
Ki-67 score. A significant positive correlation between Cyclin D1 and E was 
also detected in carcinomas. Decreased levels of Cyclins D1 and E in the group 
of in situ carcinomas compared with those of dysplastic cases and papillomas 
were  also  observed.  In  the  dysplastic  lesions  Cyclin  D1  expression  was 
correlated with pRb expression. 
In the cases of keratosis cyclins D1 and E expression were correlated with 
pRb, while Cyclin D1 was associated with PCNA and Ki-67 score. In conclusion 
the expression of Cyclins D1 and E in squamous cell carcinomas of the larynx 
does not seem to have a prognostic significance. In addition, their expression 
may be  involved in  the  development  of  laryngeal  lesions,  implicated  in  cell 
proliferation,  with  other  cell  cycle  related  proteins,  probably  by  different 
molecular pathways.  
 Overexpression of Cyclin D1 correlates with recurrence in a group of forty-
seven  operable  squamous  cell  carcinomas  of  the  head  and  neck181.
 Overexpression of Cyclin D1 was also associated with a shortened overall 
survival  of  these  patients  with  a  5-year  survival  of  60% for  the  Cyclin  D1 
strongly  positive  cases  and  of  83%  for  Cyclin  D1-negative  cases. 
Overexpression of Cyclin D1 appears to indicate poor prognosis  
Molecular and immuno histochemical analysis of the bcl-1/cyclin D1 gene in 
laryngeal squamous cell carcinomas: correlation of protein expression with 
lymph node metastases and advanced clinical stage182.
 The  molecular  pathogenesis  of  laryngeal  squamous  cell  carcinomas 
(LSCCs) is still only partially understood, although genetic alterations affecting 
various proto oncogenes or tumor suppressor genes have often been detected. To 
improve their  understanding of the  role of  Cyclin D1 in the pathogenesis  of 
LSCCs, the authors investigated the expression of Cyclin D1 protein and the 
amplification status of the bcl-1/cyclin D1 locus in a panel of  58 pathologic 
samples.  The  authors  found  almost  complete  concordance  between  locus 
amplification and protein expression. Statistical analysis showed a correlation 
between Cyclin D1 expression and both the presence of lymph node metastases 
and  advanced  clinical  stage.  The  authors'  observations  suggest  that  the 
deregulation of Cyclin D1 expression may be involved in the pathogenesis of 
more aggressive LSCCs . 
 PRAD-1/cyclin D1 gene amplification correlates with messenger RNA over 
expression and tumor progression in human laryngeal carcinomas183.
 PRAD-1 is a putative oncogene localized on chromosome 11q13 which 
encodes  Cyclin  D1,  a  novel  Cyclin  involved  in  cell  cycle  regulation. 
Amplification of this gene has recently been reported in several human tumors 
including breast and head and neck carcinomas.
 In this study we have analyzed the presence of PRAD-1/cyclin D1 gene 
amplification  and  mRNA over  expression  in  a  series  of  46  matched normal 
mucosas  and  squamous  cell  carcinomas  of  the  larynx.  DNA  amplification 
correlated with advanced local invasion), presence of lymph node metastases, 
and stage IV of the tumors.
mRNA over expression was also significantly associated with advanced 
local invasion and stage IV carcinomas. A significant association was observed 
between  gene  amplification  and  mRNA  over  expression  .Furthermore,  the 
degree of DNA amplification correlated with the levels of mRNA expression.
 These  findings  suggest  that  the  PRAD-1/cyclin  D1  gene  may  be  an 
important  target  of  11q13  amplifications  in  laryngeal  carcinomas  and  the 
activation of this gene may be involved in the progression of these tumors. Its 
association with advanced-stage tumors indicates that PRAD-1/cyclin D1 gene 
amplification and over expression may be of prognostic significance.
 
Clinical relevance of Cyclin D1 protein over expression in laryngeal 
squamous   cell carcinoma87.
 Cyclin D1 over expression was significantly associated with tobacco 
smoking and alcohol consumption, tumor extension, advanced clinical stage, and 
the presence of lymph node metastases. 
Univariate analysis showed that a shorter disease-free and overall survival 
were significantly associated with supraglottic site, tumor extension, advanced 
clinical stage, and Cyclin D1 over expression. At multivariate analysis, tumor 
extension and Cyclin D1 over expression were significantly associated with 
tumor recurrence, whereas tumor extension, supra glottic site and, at a borderline 
level of statistical significance, Cyclin D1 over expression, were associated with 
reduced overall survival. 
The over expression of Cyclin D1 in LSCC is associated with unfavorable 
clinico pathologic features and represents an independent significant predictor of 
laryngeal carcinoma prognosis, particularly for disease-free survival. This 
indicates that Cyclin D1 evaluation may be a further useful element for selecting 
subgroups of patients who should be treated with more aggressive therapies.
 
Cyclin-D1-gene amplification is  a  more  potent  prognostic  factor than its 
protein  over-expression  in  human  head-and-neck  squamous-cell 
carcinoma48.
 To  evaluate  the  prognostic  significance  of  Cyclin  D1  protein/gene 
expressions  in  human head-and-neck squamous-cell  carcinoma,  we examined 
amplification of the cyclin-D1 gene (CCND1) by the differential PCR method 
and over-expression of cyclin-D1 protein by immuno histochemistry.
The overall 5-year survival of patients with CCND1 amplification or with 
protein over-production was significantly lower than that  of patients  without. 
However, with multivariate analysis, only amplification of CCND1 retained an 
independent prognostic value .These suggest that CCND1 amplification occurs 
at early stages of HNSCC tumorigenesis and is a more useful prognostic factor 
than over-expression of CyclinD1 in HNSCC  
Cyclin D 1 : Target for therapeutic strategies 
 Antisense Cyclin D1 enhances sensitivity of head and neck cancer cells to 
cisplatin184.
 Cyclin D1 is a cell cycle regulatory factor that modulates a critical step in 
cell cycle control.  Cyclin D1 is over expressed in a significant proportion of 
head  and  neck  cancers  and  correlates  with  a  poor  prognosis.  Abrogation  of 
Cyclin D1 action through antisense Cyclin D1 shows promise as an anti tumor 
therapy, with an inhibitory effect in head and neck squamous cell  carcinoma 
both in vitro and in vivo. 
The suppressive effect of antisense Cyclin D1 in head and neck cancer 
xenografts in nude mice is incomplete,  however,  suggesting that combination 
with  another  antitumor  agent  is  necessary  for  complete  tumor  eradication. 
Cisplatin is a widely used chemotherapeutic agent in head and neck cancer, and 
is particularly effective in combination with radiation therapy. 
In this study, we investigate whether antisense Cyclin D1 enhances the 
sensitivity of head and neck cancer cells to cisplatin. Such an enhancement of 
sensitivity would suggest that combination therapy using antisense Cyclin D1 
and cisplatin would be an effective treatment modality for head and neck cancer. 
Increasing concentrations of cisplatin resulted in significantly higher rates 
of cell killing in the antisense Cyclin D1-transfected cells than in the parental 
cells.. Western blot analyses demonstrated decreased expression of Cyclin D1 in 
the  CCL23AS  cells  with  increasing  doses  of  cisplatin,  compared  with  the 
parental CCL23 cells. 
Antisense Cyclin D1-transfected CCL23 cells demonstrate an enhanced 
sensitivity  to  the  effects  of  cisplatin  compared  with  the  parental  cell  line. 
Although the mechanism for this phenomenon is not completely understood, the 
data suggests the potential use of combination therapy using antisense Cyclin D1 
and cisplatin for head and neck cancers. 
While  neither  agent  alone  can  completely  eradicate  head  and  neck 
cancers,  the  synergistic  effect  of  the  two  may  be  an  effective  therapeutic 
protocol  for  refractory  head and neck cancers.   Future  investigation  into the 
combination of antisense Cyclin D1 with cisplatin for  treatment of head and 
neck cancer is needed. 
Prognostic  significance  of  P27  and Cyclin  D1 co-expression  in  laryngeal 
squamous cell carcinoma: possible target for novel therapeutic strategies165.
 Tumor cells are characterized by uncontrolled growth due to alterations in 
the genes that play a key role in cell repair systems and apoptosis: pro-mitotic 
oncogenes such as Cyclin D1, and tumor suppressor genes such as p27. Recent 
studies have demonstrated that these genes are involved in different epithelial 
neoplasms  and  that  their  expression  is  generally  associated  with  prognosis. 
Multivariate analysis showed that Cyclin D1 and p27 were the only statistically 
significant predictors of disease-free and overall survival. 
In relation to the simultaneous expression of p27 protein and Cyclin D1, 
the patients with a Cyclin D1+/p27-phenotype had the poorest disease-free and 
overall survival rates. On the basis of these immuno histochemical results, it was 
possible to select a subgroup of patients with a high risk of recurrence and poor 
prognosis to undergo more extended surgical treatment and/or combination anti 
tumoral therapeutic procedures. 
CHAPTER 4
RESULTS  
This study was done by Immuno histochemically. The controls used were 
sections from squamous cell carcinoma of larynx known to over express Cyclin 
D1. The negative control had omission of the primary antibody. Only nuclear 
staining of cells was taken as positive. Whole of the stained section was studied 
microscopically under 40 X magnification. 
Scores were ranked as – negative;  +/- 0-5 % tumor cells were positive; + 
5-50%  of  tumor  cells  were  positive;  ++  >50  %  of  tumor  cells  were 
positive.87,107,181
4.1 Cyclin D 1 expression in normal laryngeal epithelium
           Normal laryngeal epithelium does not express Cyclin D 1 or sometimes 
weak staining may be present.
i. Cyclin D 1 expression in laryngeal cancer
            In head and neck squamous cell carcinoma the most commonly studied 
Cyclin has been Cyclin D 1. 35-64% of head and neck cancers87, 111,172,181 have 
been reported to over express Cyclin D 1 or to have CCND 1 gene amplification. 
Table 3
CLINICOPATHOLOGICAL PARAMETERS
Variable Number
N=74
Percentage
Sex
Male 71 95.9%
Female 3 4.1%
Age
< 60 years 22 29.8%
> 60 years 52 70.2%
Subsite
Supra glottis 15 20.3%
Glottis 47 63.5%
Trans glottis 12 16.2%
T Status 
T 1a 12 16.2%
T 1b 6 8.1%
T 2 24 32.4%
T 3 17 23.0%
T 4 15 20.3%
N status 
N 0 50 67.6%
N 1 7 9.5%
N 2a 1 1.4%
N 2b 9 12.2%
N 2c 5 6.8%
N 3 2 2.7%
Table 4
Variable Number
N=74
Percentage
Stage
1 16 21.6%
2 15 20.3%
3 13 17.6%
4 30 40.5%
Grade
G 1 7 9.5%
G 2 25 33.8%
G 3 35 47.3%
G x 7 9.5%
G x     Grade not known
Treatment 
Radiotherapy only 51 68.9%
Surgery only 4 5.4%
Surgery and post 
operative Radiotherapy
17 23.0%
Radiotherapy and salvage 
Surgery
2 2.7%
Relationship between age and cyclin D 1 expression
AGE(years)
CyclinD1expression
Negative Percentage Positive Percentage
<30 1 2.0 0 0.0
31- 40 3 5.9 1 4.3
41-50 11 21.6 6 26.1
51-60 18 35.3 6 26.1
61-70 12 23.5 7 30.4
71-80 6 11.8 3 13.0
P value = 0.9253
Table 5
Relationship between subsite and cyclin D 1 expression
SUBSITE
Cyclin D1 expression
Negative Percentage Positive Percentage
Supra glottis 9 17.6 6 26.1
Glottis 33 64.7 14 60.9
Trans glottis 9 17.6 3 13.0
P value = 0.6700
Table 6
 Relationship between T status and   cyclin D 1 expression
T  STATUS
Cyclin D1 expression
Negative Percentage Positive Percentage
T 1a 6 11.8 6 26.1
T 1b 3 5.9 3 13.0
T 2 16 31.4 8 34.8
T 3 11 21.6 6 26.1
T 4 15 29.4 0 0.0
P value = 0.0409, significant
Table 7
 Relationship between N status and cyclin D 1 expression
N STATUS
Cyclin D1 expression
Negative Percentage Positive Percentage
Node negative 36 70.6 14 60.9
Node positive 15 29.4 9 39.1
P value = 0.5766
Table 8
Relationship between stage and cyclin D 1 expression
STAGE
Cyclin D1 expression
Negative Percentage Positive Percentage
I & II 23 45.1 7 30.4
III & IV 28 54.9 16 69.6
P value = 0.3506
Table 9
Relationship between grade of tumor and cyclin D 1 expression
GRADE  
Cyclin D1 expression
Negative Percentage Positive Percentage
G 1 5 9.8 2 8.7
G 2 19 37.3 6 26.1
G 3 23 45.1 12 52.2
G x 4 7.8 3 13.0
P value = 0.7465
Table 10
 Distribution of mean and standard deviation of time (in months) to 
recurrence and cyclin D 1 expression
Cyclin D 1
expression
Number of 
recurrences
Mean ± SD Median P value
 
Negative 6 8.8 ± 6.0 8.0
0.247
 
Positive 4 18.3±17.5 12.5
 Table 11
Distribution of mean and standard deviation of time (in months) to residual 
disease after primary radiotherapy and cyclin D 1 expression
Cyclin D 1
expression
Number of 
residues
Mean ±  SD Median P value
 
Negative 5 6.8 ± 2.6 8.0
0.699
 
Positive 8 7.6 ± 4.1 7.5
Fig. 5 Squamous cell carcinoma of larynx- Cyclin D1 expression is negative 
Fig. 6 Squamous cell carcinoma of larynx - Cyclin D1 expression is 10 percent 
Fig.7 Squamous cell carcinoma of larynx - Cyclin D1 expression is 20 percent
Fig. 8 Squamous cell carcinoma larynx-Cyclin D1 expression is 30 percent
 
Fig.9 Squamous cell carcinoma of larynx- Cyclin D1 expression, 50 percent
Fig.10 Squamous cell carcinoma of larynx-Cyclin D1 expression, 80 percent
Fig.11 Squamous cell carcinoma of larynx- Cyclin D1 expression, 80 percent
Fig.12 Squamous cell carcinoma of larynx- Cyclin D1 expression, 80 percent
CHAPTER 5
DISCUSSION
        The cyclin D1 gene plays a pivotal role in the regulation of the cell cycle89. 
During  the  middle  to  late  G1phase90,  it  complexes  with  cdk4  or  cdk6,  thus 
promoting the phosphorylation of the pRb gene product and, finally, progression 
to the S phase91
Experimental  observations  indicate that  a  moderate over  expression of 
Cyclin D 1 leads to a shortening of the G1 phase and less dependence on growth 
factors for cell proliferation. 102,103 .
It has likewise also been recently reported that antisense to Cyclin D 1 is 
capable of inhibiting the growth and tumorigenicity of human colon cancer cells, 
which thus suggests that increased cyclin D1 expression might contribute to the 
abnormal growth of tumor cells104
Cyclin Dl gene aberrations are frequently detectable in head and neck 
tumors105-110, 88,111-113 especially in carcinomas of the hypopharynx and, to a lesser 
extent, in those of the oropharynx and larynx114-116
 It has been shown that cyclin D1 can become deregulated as a result of 
various genetic lesions, including chromosomal inversion and translocation in 
parathyroid  adenomas  and  B-cell  non-Hodgkin  lymphomas  92,  93 or  gene 
amplification in carcinomas of the breast 94, 95 liver96 pancreas 97 esophagus 98anus 
98ovary99bladder 100 and lung 101
A separate prognostic role has been described for Cyclin D1 protein over 
expression 87 and CCND1 gene amplification 88, with an impact on relapse-free 
and overall survival in HNSCC. Studies on breast tumors and also on HNSCC 
have  shown  that  CCND1 amplification,  rather  than  protein  over  expression, 
might have prognostic value 119. 
                 Cyclin D1 gene transcriptional activity normally strictly depends on  
mitogen stimulation, and leads to cell commitment to mitosis through START 
checkpoint.  An  early  CCND1  over  expression  is  often  detectable  without 
evidence of gene amplification; it can be used for molecular epidemiology but it 
seems  to  retain  a  lower  prognostic  value,  if  compared  with  CCND1 
amplification, a marker of aggressiveness in LSCC 88.
  It  has  been  reported  that  Cyclin  D  1  amplification  and/or  over 
expression  are  associated  with  unfavorable  clinico  pathologic  features114,  116 
tumor recurrence, and a poor prognosis111, 115,117,118
         Out of 74 samples studies,    Cyclin D 1 protein was over expressed in 
more than 5% of cells of 23 samples (31.1%) studied, whereas other studies of 
tumors of the head and neck region (which included only a small number of 
laryngeal  carcinomas)  has  reported  that  cyclin  D1 was  expressed  in  35% to 
64%87,111,172,181 
         This apparent discrepancy might be explained by the fact that all of these 
studies included tumors of hypopharynx, in which Cyclin  D 1 aberrations have 
been represent a common event in this regard, it is worth noting that Masuda 
et  al.,.185 found  cyclin  D 1  over  expression  in  55% of  their  hypopharyngeal 
carcinomas.
          In this study, Cyclin D 1 over expression was not significantly associated 
with  unfavorable  clinico  pathologic  features  such  as  advanced  clinical  stage 
(p=0.3506) and presence of lymphnode metastasis (p=0.5766). This data is in 
contrast to other studies 87,107,181 where both advanced stage and nodal metastasis 
were associated with Cyclin D 1 over expression and poor outcome 
          There was a significant association with Cyclin D 1 expression and extent 
of tumor (T status) in this study   (p=0.0409). This is in line with that of other 
studies.  
           Cyclin D 1 expression was not significantly associated with Age  
of the patient, Grade of the tumor and anatomical subsite of tumor in the larynx.
         In contrast to many studies which show Cyclin D 1 over expression and its 
association with poor outcome in laryngeal cancer87,  107,172,181 this study did not 
show any association with time to recurrence of the tumor and time to residual 
disease after treatment with Radiotherapy. 
CONCLUSION
 In this study only the Extent of tumor (T status)   correlates with the over 
expression of Cyclin D 1. 
Otherwise this study did not support the hypothesis that Cyclin D1 over 
expression is an independent significant predictor for Stage of disease, Nodal 
status, Grade of tumor or Recurrence of disease. 
 Possibly Cyclin D 1 gene amplification may be better prognosticator than it’s 
protein over expression as studied by Bellacosa et.al.88, Kyomoto et.al, 116.
Distinct molecular pathways at different anatomical regions involved, not only 
in the abnormal function of the Cyclin D 1 cell cycle regulator, but also in the 
development of tumors without Cyclin D 1 alteration.186
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